Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0032 | 0.2942 | 0.0872 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0071 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0032 | 0.2942 | 0.2942 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0032 | 0.2942 | 0.2432 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0032 | 0.2942 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0071 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0032 | 0.2942 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0071 | 1 | 1 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0071 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0029 | 0.2268 | 0.5 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0071 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0032 | 0.2942 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.2942 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.003 | 0.2608 | 0.8529 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.002 | 0.0674 | 0.0674 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0032 | 0.2942 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0071 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.003 | 0.2608 | 0.8529 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0032 | 0.2942 | 0.2432 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0032 | 0.2942 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0032 | 0.2942 | 0.0872 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0032 | 0.2942 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.0032 | 0.2942 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0032 | 0.2942 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 0.2942 | 0.2432 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 0.2942 | 0.2432 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0029 | 0.2268 | 0.5 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0071 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0032 | 0.2942 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.002 | 0.0674 | 0.5 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0071 | 1 | 0.5 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0071 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.53 uM | In vitro inhibition of human Inducible nitric oxide synthase. | ChEMBL. | 15163211 |
IC50 (binding) | = 0.53 uM | In vitro inhibition of human Inducible nitric oxide synthase. | ChEMBL. | 15163211 |
IC50 (binding) | = 28 uM | In vitro inhibition of human neuronal nitric oxide synthase. | ChEMBL. | 15163211 |
IC50 (binding) | = 28 uM | In vitro inhibition of human neuronal nitric oxide synthase. | ChEMBL. | 15163211 |
IC50 (binding) | = 100 uM | In vitro inhibition of human endothelial nitric oxide synthase. | ChEMBL. | 15163211 |
IC50 (binding) | = 100 uM | In vitro inhibition of human endothelial nitric oxide synthase. | ChEMBL. | 15163211 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.